-
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
July 22, 2026 02:00 ET | Source: Healx Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination…
-
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
GENEVA, June 27, 2026 /PRNewswire/ — Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is widely recognised as the largest modifiable risk…
-
SLEEPING WITH THE ENEMY: 68% OF UK FANS WOULD RATHER DATE SOMEONE WHO HATES FOOTBALL THAN A RIVAL SUPPORTER
LONDON, UK — 19 March 2026 — It is the ultimate test of modern romance: can love survive the local derby? According to new research, the answer is a resounding “no.” A new national dating survey by the BT4Y Data Lab of 2,500 UK adults reveals that football tribalism is officially dictating the country’s dating…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.